Sino Biopharmaceutical Limited (SBHMY) Stock Price & Analysis
Sino Biopharmaceutical Limited (SBHMY) — price $16.28 (0.00%), as of the Oct 2, 2026 trading session; market cap $14.5B.
Educational signal · not a buy or sell recommendation · How to read this
Sino Biopharmaceutical Limited · SBHMY · Healthcare · Medical - Pharmaceuticals
Sino Biopharmaceutical Limited operates as a prominent research and development-centric pharmaceutical conglomerate in the People's Republic of China, functioning as an investment holding company.
Price as of Oct 2, 2026
Key Statistics
MoonshotScore is not published for this security.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $16.28 | |
| Change on the day | 0.00% | |
| 52-week range | $11.27 – $20.16 | |
| Market capitalisation | $14.5B | |
| Price / earnings (trailing) | 35.80 | |
| Shares traded on the day | 202 | |
| Beta (volatility vs the S&P 500) | 0.61 | |
| Dividends per share (last 12 months) | $0.31 | |
| Dividend yield (last 12 months) | 1.88% |
Price & events
Point at or tab to any week for its close.
Upcoming events
Other perspectives
Council score for Sino Biopharmaceutical (SBHMY): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
9-Factor Breakdown
Legends Council
5 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 9, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Oct 5, 2026, except a card that shows its own read date.
Watch the SBHMY film — every key number, told as a short cinematic story
~2 min · open the film
What is Sino Biopharmaceutical (SBHMY), and what does it report?
Short answer · as of
Sino Biopharmaceutical Limited operates as a prominent research and development-centric pharmaceutical conglomerate in the People's Republic of China, functioning as an investment holding company. Healthcare / Medical Pharmaceuticals Headquarters: Unit 09, Office Tower, Hong Kong, HK. It employs 21,435 people and is led by S. Y. Tse. In Q2 FY2026 it reported revenue of $1.45B and net income of $256M. The market values it at $14.5B.
What do the latest results show for Sino Biopharmaceutical (SBHMY)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $1.45B.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $1.23B Aug 15, 2025
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Aug 15, 2025 | $1.23B | Not available | $0.2621 | Not available |
| Mar 26, 2025 | $889.68M | Not available | $0.0018 | Not available |
| Mar 20, 2025 | $925.73M | Not available | $0.0019 | Not available |
| Aug 13, 2024 | $1.09B | Not available | $0.0113 | Not available |
Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $1.45B | $256M | $0.28 (diluted) |
| Q1 FY2026 | $1.45B | $256M | $0.28 (diluted) |
| Q4 FY2025 | $1.06B | -$78M | -$0.09 (diluted) |
| Q3 FY2025 | $1.06B | -$78M | -$0.09 (diluted) |
What are the financial strengths and risks for Sino Biopharmaceutical (SBHMY)?
Short answer
The distress and quality screens read Altman Z 2.60 · Piotroski F 6. Trailing ratios: ROE 7.2% · ROA 3.1% · current ratio 1.37 · earnings yield 3.3% · free-cash-flow yield 4.1%.
What Investors Ask About Sino Biopharmaceutical (SBHMY) — Healthcare
Research dated 2026-09-13; the answers below are from that research, and the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
How do Qingkeshu and Leweixin fit Sino Biopharmaceutical’s business?
Qingkeshu tablets and Leweixin injections are oncology products within a much broader medicine portfolio. Their presence illustrates the group’s therapeutic breadth rather than defining Sino Biopharmaceutical as an oncology-only company.
What is the SBHMY stock price today?
The last price recorded on this page for Sino Biopharmaceutical Limited (SBHMY) is $16.28, as of the Oct 2, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
Does SBHMY pay a dividend?
Yes. Sino Biopharmaceutical Limited (SBHMY) shows a trailing 12-month dividend yield of 1.88%, as of Oct 2, 2026, in the data on this page. Payout ratio and cash-flow coverage decide whether it can last, and past dividends do not guarantee future payments.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are shown with each answer. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (29 figures)
The 29 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
FMP — 24 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $16.28 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-05T00:54:34.168Z. | |
px.change | Change on the day | 0.00% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $14.5B | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-02. FMP quote timestamp: 2026-10-02T20:00:00.000Z. Captured from FMP at 2026-10-05T00:54:33.185Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
id.business_summary | Business description (FMP excerpt) | Sino Biopharmaceutical Limited operates as a prominent research and development-centric pharmaceutical conglomerate in the People's Republic of China, functioning as an investment holding company. | FMP | Financial Modeling Prep (FMP) company profile — Deterministic excerpt derived from id.description; source and date describe the input fact, not a new provider observation | |
px.change_abs | Change on the day, in dollars | $0.00 | FMP | Financial Modeling Prep (FMP) · quote | |
px.pe | Price / earnings (trailing) | 35.80 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 202 | FMP | Financial Modeling Prep (FMP) · quote | |
px.beta | Beta | 0.61 | FMP | Financial Modeling Prep (FMP) company profile | |
id.sector | Sector / industry (provider taxonomy) | Healthcare / Medical Pharmaceuticals | FMP | Financial Modeling Prep (FMP) company profile | |
id.hq | Headquarters | Unit 09, Office Tower, Hong Kong, HK | FMP | Financial Modeling Prep (FMP) company profile | |
id.employees | Employees | 21,435 | FMP | Financial Modeling Prep (FMP) company profile | |
id.ceo | Chief executive | S. Y. Tse | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) — Titles and pay come from the company's proxy statement as our provider parsed it. | |
fin.q_revenue | Revenue, Q2 FY2026 | $1.45B | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_income | Net income, Q2 FY2026 | $256M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
id.founder | Founder named in the filing | Ping Tse — Founder & Senior Executive Vice Chairman | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) — Titles and pay come from the company's proxy statement as our provider parsed it. | |
earn.history.depth.2025-08-15.revenue_actual | Revenue · reported — report date 2025-08-15 | $1.23B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-08-15.eps_actual | EPS · reported — report date 2025-08-15 | $0.2621 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-03-26.revenue_actual | Revenue · reported — report date 2025-03-26 | $889.68M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-03-26.eps_actual | EPS · reported — report date 2025-03-26 | $0.0018 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-03-20.revenue_actual | Revenue · reported — report date 2025-03-20 | $925.73M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-03-20.eps_actual | EPS · reported — report date 2025-03-20 | $0.0019 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2024-08-13.revenue_actual | Revenue · reported — report date 2024-08-13 | $1.09B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2024-08-13.eps_actual | EPS · reported — report date 2024-08-13 | $0.0113 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
fin.q_table | Quarterly income statement | 4 quarters through Q2 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed |
UNRECORDED — 3 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.range52 | 52-week range | $11.27 – $20.16 | UNRECORDED | Stored company-profile observation — Captured 2026-10-03 | |
fin.scores | Distress and quality screens | Altman Z 2.60 · Piotroski F 6 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-04 | |
fin.ratios | Return and yield ratios (trailing twelve months) | ROE 7.2% · ROA 3.1% · current ratio 1.37 · earnings yield 3.3% · free-cash-flow yield 4.1% | — | UNRECORDED | Stored key metrics — Date unknown |
COMPUTED — 2 facts from our arithmetic, formula restated
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
div.ttm_per_share | Dividends per share, last 12 months (split-adjusted) | $0.31 | COMPUTED | Financial Modeling Prep (FMP) split-adjusted dividend history — Sum of 2 split-adjusted declared dividends with an ex-date in the 365 days to 2026-10-04, per current share. Ex-dates are not payment dates; special dividends are included. Not a declared annual rate. | |
div.ttm_yield | Dividend yield, last 12 months | 1.88% | COMPUTED | Financial Modeling Prep (FMP) split-adjusted dividend history and quote — Split-adjusted dividends with ex-dates in the trailing 365-day window divided by the packet price, on the same current-share basis. Price date follows the quote, latest price bar or packet-build day when unstamped. Not a forecast or declared annual rate. |
Fact-family notes
- Earnings-history note. Source series as of 2025-08-15. Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined. Applies to Fact IDs:
earn.history.depth.2025-08-15.revenue_actual,earn.history.depth.2025-08-15.eps_actual,earn.history.depth.2025-03-26.revenue_actual,earn.history.depth.2025-03-26.eps_actual,earn.history.depth.2025-03-20.revenue_actual,earn.history.depth.2025-03-20.eps_actual,earn.history.depth.2024-08-13.revenue_actual,earn.history.depth.2024-08-13.eps_actual.
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources used for research written 2026-09-13
Historical evidence preserved with this analysis. Current figures are listed separately above.
| Evidence | Captured value | Source date | Source type | Source |
|---|---|---|---|---|
| Business description | Sino Biopharmaceutical Limited operates as a prominent research and development-centric pharmaceutical conglomerate in the People's Republic of China, functioning as an investment holding company. Its operations are organized into three primary divisions: Modernized Chinese and Chemical Medicines, Investment activities, and other varied business ventures. The firm maintains an extensive product range covering numerous therapeutic categories. Among its offerings are oncology treatments, such as Qingkeshu tablets and Leweixin injections; cardiovascular and cerebrovascular medications, including Kaina and Anrixin tablets; hepatitis remedies like Tianqingganmei injections; and orthopedic solutions exemplified by Gaisanchun capsules. The company also produces drugs for respiratory ailments and parenteral nutritional support, for instance, Xinhaineng injections, along with a broad spectrum of other pharmaceutical preparations, such as Tuotuo tablets. Additionally, Sino Biopharmaceutical provides a selection of advanced pharmaceutical agents, including Aprepitant, Lenvatinib Mesilate, Vortioxetine Hydrobromide, and Edaravone injection. Its portfolio also features combination therapies like Amlodipine Besylate and Atorvastatin Calcium, alongside Sofosbuvir, Sitagliptin Phosphate, Colistimethate Sodium for injection, and Tofacitinib Citrate. Beyond its core pharmaceutical manufacturing, the company's diverse business interests encompass property holdings, the retail and distribution of pharmaceutical products, and providing optometry services coupled with the sale of ophthalmic goods. It manages hospitals, delivers medical management and health information consultancy, and offers biotechnology transfer and consultation services. The enterprise is also involved in the production and sale of health foods, provides orthopedic outpatient care and surgical procedures, engages in medical and health technology development, trades optical glasses, and conducts research, development, and commercialization of medical devices and active pharmaceutical ingredients. Established in 2000, the company's corporate headquarters are situated in Wan Chai, Hong Kong. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) company profile |
Data provided for informational purposes only.